Vericel (VCEL) to Release Earnings on Thursday

Vericel (NASDAQ:VCEL - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, July 31st. Analysts expect Vericel to post earnings of ($0.04) per share and revenue of $64.61 million for the quarter. Vericel has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a return on equity of 1.09% and a net margin of 1.25%. The business had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. During the same quarter in the prior year, the firm posted ($0.08) earnings per share. The business's revenue was up 2.6% compared to the same quarter last year. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vericel Stock Up 1.0%

Shares of NASDAQ VCEL traded up $0.40 during midday trading on Friday, hitting $40.12. 345,053 shares of the company's stock were exchanged, compared to its average volume of 548,394. Vericel has a 12 month low of $34.87 and a 12 month high of $63.00. The company's 50 day moving average price is $41.16 and its 200 day moving average price is $46.19. The firm has a market capitalization of $2.02 billion, a PE ratio of 1,337.78 and a beta of 1.32.

Hedge Funds Weigh In On Vericel

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VCEL. Goldman Sachs Group Inc. raised its holdings in Vericel by 13.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company's stock valued at $16,576,000 after acquiring an additional 44,333 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Vericel by 9.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,028 shares of the biotechnology company's stock worth $5,490,000 after buying an additional 10,191 shares in the last quarter. AQR Capital Management LLC acquired a new position in shares of Vericel during the 1st quarter worth $242,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Vericel by 6.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,445 shares of the biotechnology company's stock worth $1,403,000 after buying an additional 1,847 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen downgraded Vericel from a "hold" rating to a "sell" rating in a research note on Monday, May 12th. Stephens restated an "overweight" rating and issued a $67.00 price target on shares of Vericel in a research note on Monday, June 16th. Finally, Truist Financial reduced their price target on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Vericel presently has an average rating of "Moderate Buy" and a consensus target price of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.